Defining the Role of BTLA in Breast Cancer Immunosurveillance and Selective Targeting of the BTLA-HVEM-LIGHT Constimulatory System
Abstract
The current reporting period represents the second year of the award. In the first year the primary goals of generating crosses between various genetic strains of mice were initiated. In the repost for the first year, described the discovery of a use for BTLA that could be applied to treatment of breast cancer in an unanticipated manner. One therapy used to treat metastatic breast cancer is autologous stem cell transplantation, or bone marrow transplantation (BMT), which however can cause serious or even lethal graft versus host disease (GvHD). GvHD therefore presents a real limitation to the use of BMT in treating metastatic breast cancer. In our previous report, we described our discovery that administration of anti-BTLA antibodies at the time of bone marrow transplantation permanently prevent GvHD in murine models. In the second year, we pursued to determine the mechanistic basis for this effect. This work was very successful, and we have now published our study in the Journal of Experimental Medicine.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2011
- Accession Number
- ADA545725
Entities
People
- Kenneth M. Murphy
- William E. Gillanders
Organizations
- Washington University in St. Louis